Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
mesenchymal stem cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral Vascular Disease
1 trial -
pCAR-19B cells
Chongqing Precision Biotech Co., Ltd
Acute Lymphoblastic Leukemia, in Relapse
1 trial -
pd-1 and DC-NK cells
The First People's Hospital of Lianyungang
Solid Tumor
1 trial -
pd-1 and dc-cik cells
The First People's Hospital of Lianyungang
Solid Tumor
1 trial -
prophylactic 4SCAR19 cells
The First People's Hospital of Lianyungang
B Acute Lymphoblastic Leukemia
1 trial -
stem cells
The First People's Hospital of Lianyungang
Diminished Ovarian Response
1 trial -
universal CLL1 CAR-T cells
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Alofisel 5 Γ 106 cells/mL dispersion for injection.
Takeda
Perianal fistulising CrohnΒ΄s disease
1 trial -
Cytokine-induced killer cells+ FOLFOX4
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colorectal Cancer
1 trial -
EV71 inactived vaccineοΌVero cellsοΌ
Sinovac Research and Development Co.,
Hand, Foot and Mouth Disease
1 trial -
inactivated EV71 vaccine (KMB-17 cells)
Chinese University of Hong Kong
Hand, Foot and Mouth Disease (HFMD)
1 trial -
mesenchymal stromal cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
MSC
1 trial -
Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Autoimmune Diseases
1 trial -
Anti-HER2 CAR-T cells
The First People's Hospital of Lianyungang
HER2-positive Advanced Malignant Solid Tumors
1 trial -
CAR-T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Philadelphia Positive Acute Lymphoblastic Leukemia
1 trial -
CD19 CAR-T cells infusion
The First People's Hospital of Lianyungang
Non Hodgkin Lymphoma
1 trial -
CT0590 CAR T Cells
The First People's Hospital of Lianyungang
Relapsed and/or Refractory Multiple Myeloma
1 trial -
Human umbilical cord mesenchymal stem cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Knee Osteoarthritis
1 trial -
LCAR- F33S cells intravenous infusion
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed/Refractory Multiple Myeloma(MM)
1 trial -
LCAR-M61S cells preparation
Nanjing Legend Biotech Co.
Relapsed/Refractory Multiple Myeloma
1 trial -
Mononuclear cells
Shandong Provincial Hospital
Chronic Atrophic Gastritis
1 trial -
Tumor Specific Antigen-loaded Dendritic Cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Tumor Gastric
1 trial -
anti-CD19/BCMA-UCAR-T cells
The First People's Hospital of Lianyungang
Rheumatoid Arthritis
1 trial -
circulating tumor cells test
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Thyroid Nodule
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources